No acquisition but Roche/Chugai rejig alliance terms
This article was originally published in Scrip
After rumors of a planned Roche buy-out of Chugai failed to materialize, the two companies have instead restructured some of the key terms of their original 2001 strategic alliance, in a change that will give Roche broader access and rights to Chugai's pipeline.
You may also be interested in...
While Chugai’s satralizumab may not be odds on to win the race for approval, it may beat Alexion’s Soliris on ease of use with a regimen of subcutaneous application once a month versus Soliris’ fortnightly IV.
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.